Archive: 09/09/2019
Tumor mutational burden not significantly associated with efficacy of pembrolizumab
Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according ...
Sep 9, 2019